ABL Diagnostics to Present Breakthrough Scientific Data at the European Meeting on HIV & Hepatitis 2025

Featuring New Advances in Automated Bioinformatics and HIV Drug Resistance Detection Using Next-Generation Sequencing

WOIPPY, FRANCE, June 4, 2025 /EINPresswire.com/ -- ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed leader in molecular diagnostics, is proud to announce its participation at the European Meeting on HIV & Hepatitis 2025, taking place in Barcelona, Spain, from June 4 to 6, 2025. The company will unveil two new scientific posters showcasing cutting-edge innovations in viral genome analysis and HIV drug resistance detection.

Poster #39: Automated, Large-Scale and Secure Bioinformatics for Comprehensive Analysis of Viral Genomes Using MicrobiocheK^®

This study highlights MicrobiocheK^®, ABL's advanced bioinformatics platform engineered for complete genome analysis of key viral pathogens including HIV-1, RSV A/B, Hepatitis Delta, Influenza A/B, and SARS-CoV-2. The platform integrates:
- Automated workflows for data processing, quality control, alignment, and variant calling
- Real-time access to curated HIV variant databases (Stanford, ANRS, Rega, Geno2pheno)
- Secure cloud-based infrastructure compliant with HDS (Healthcare Data Hosting) standards
- Seamless interoperability with Nadis^®(http://www.nadis.fr), a specialized electronic medical record for infectious disease monitoring

The results demonstrated the platform’s high scalability, rapid deployment, and accurate detection of subtypes and mutations, including SARS-CoV-2 and RSV clades, even across large datasets. Clinical reporting features provided actionable insights for healthcare professionals.

“MicrobiocheK^® proves that automation, scalability, and security can coexist in a single platform designed for modern-day genomic surveillance. This marks a major advancement for real-time, clinically relevant viral genome analysis,” said Dr. Sofiane Mohamed, Head of Research & Development at ABL Diagnostics.

Poster #60: HIV-1 Drug Resistant Minority Mutations Detection Using the MGI DNBSEQ-E25 Next-Generation Sequencing Platform

This poster presents the first evaluation of the DNBSEQ-E25 (MGI) platform in detecting HIV-1 drug-resistant minority variants using DeepChek^® HIV assays and QCMD reference samples. Key findings include:
- High sequencing accuracy, with Q30 scores outperforming traditional Illumina platforms
- Full genotyping and subtype identification across B, C, 02_AG, and 57_BC forms
- 100% concordance across MGI and Illumina platforms for drug resistance mutations >5%
- Superior sensitivity of the DNBSEQ-E25 in detecting minority mutations (3–20%) linked to resistance

“Our data confirm that MGI’s E25 platform, combined with DeepChek^® assays, is not only equivalent but in some aspects superior to existing technologies. It is a powerful tool for expanding access to NGS-based resistance testing in routine clinical settings,” added Dr. Sofiane Mohamed.

***

ABOUT ABL DIAGNOSTICS
ABL Diagnostics specializes in proprietary molecular biology assays and end-to-end solutions for precise molecular detection and genotyping:
- UltraGene – real-time PCR-based molecular detection.
- DeepChek^®– DNA sequencing for genotyping.

Expanding Portfolio for Microbiology
Our growing portfolio covers:
- HIV diagnostics – Drug resistance assays, including a Whole Genome Kit.
- SARS-CoV-2, Tuberculosis, Hepatitis B & C – Advanced genotyping and drug resistance analysis
- Microbiome & Taxonomy – 16s/18s RNA-based analysis.
- Other viral & bacterial targets – Comprehensive molecular assays.

Syndromic & Digital Solutions
- Syndromic Real-Time PCR assays (known-how and IP acquired in 2025).
- Nadis^®– EMR system used in 200+ hospitals in France for HIV & Hepatitis infected patients management.

ABL Diagnostics, based in Woippy, is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6). For further information, please visit www.abldiagnostics.com.

CONTACTS

ABL Diagnostics SA
72C route de Thionville - 57140 WOIPPY
FRANCE
Tel : +33 (0)7 83 64 68 50
Email : info@abldiagnostics.com
https://www.abldiagnostics.com

Dr Sayada
ABL Diagnostics SA
+33 7 83 64 68 50
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.